Old and New Biological Therapies for Psoriasis
Top Cited Papers
Open Access
- 1 November 2017
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 18 (11), 2297
- https://doi.org/10.3390/ijms18112297
Abstract
Biological therapy became available for psoriasis with the introduction of alefacept at the beginning of this century. Up to then, systemic treatment options comprised small molecule drugs, targeting the immune system in a non-specific manner. The first biologics targeted T-cell activation and migration and served as an alternative to small molecules. However, significant improvement in outcome was first accomplished with the introduction of tumor necrosis factor-α inhibitors that were already approved for other inflammatory disorders, including rheumatic diseases. Along with the progress in understanding psoriasis pathogenesis, highly targeted and effective therapies have since developed with the perspective not only to improve but to clear psoriasis. These accomplishments enable future achievement of advanced goals to individualize treatment best suited for each patient. Mechanistic studies with patients treated with the new highly targeted biologics may guide us towards these goals. This review offers an overview of biologics developed for psoriasis and illustrate a historical progress in the treatment of this common chronic inflammatory skin condition.Keywords
This publication has 124 references indexed in Scilit:
- Pivotal Role of Dermal IL-17-Producing γδ T Cells in Skin InflammationImmunity, 2011
- Assessing Long-Term Drug Safety: Lessons (Re) Learned from RaptivaSeminars in Cutaneous Medicine and Surgery, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisThe New England Journal of Medicine, 2010
- Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research DatabaseEuropean Heart Journal, 2009
- PsoriasisThe New England Journal of Medicine, 2009
- Structure and signalling in the IL-17 receptor familyNature Reviews Immunology, 2009
- Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasisThe Journal of Experimental Medicine, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseThe New England Journal of Medicine, 2005